Having trouble accessing articles? Reset your cache.

Flagship takes a deep dive into chromatin biology with Omega’s launch

How Flagship turns one investment in a therapeutic white space into a stronghold

With the launch of Omega, Flagship is strengthening its foothold in chromatin biology.

The VC launched Omega Therapeutics Inc. from its Flagship Labs incubator on Sept. 23 with undisclosed funding to selectively tune gene expression by targeting small loops of DNA in the 3-D chromatin structure called Insulated Genomic

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers